3 days popular7 days popular1 month popular3 months popular

For Metastatic Melanoma, Should High-Dose Interleukin-2 Continue To Be The Treatment Of Choice?

Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage . An article published in the current issue of and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, , explores whether or not this regimen is still the most effective. The article is available free online at the Cancer Biotherapy and Radiopharmaceuticals website.*

In the article “Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?” ** and colleagues at the and Hoag Family Cancer Institute, Newport Beach, CA concluded that until long-term survival data for some of the newer drugs are available, patients with stage IV metastatic melanoma who are well enough to be given intensive IL-2 therapy should receive it initially, either alone or in combination with one of the newer therapeutic agents.

“This is an important article that puts into perspective the reasons why IL-2 should continue to be the initial therapy in patients with metastatic melanoma,” says Editor Donald J. Buchsbaum, PhD, Division of Radiation Biology, , University of Alabama at Birmingham.

Source

* http://www.liebertpub.com/cbr
** http://online.liebertpub.com/doi/full/10.1089/cbr.2012.1220
Mary Ann Liebert, Inc./Genetic Engineering News